Cover Image
市場調查報告書

復發性多形性膠質母細胞瘤(GBM) - 開發中產品分析

Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 271838
出版日期 內容資訊 英文 420 Pages
訂單完成後即時交付
價格
Back to Top
復發性多形性膠質母細胞瘤(GBM) - 開發中產品分析 Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2016
出版日期: 2016年10月19日 內容資訊: 英文 420 Pages
簡介

復發性多形性膠質母細胞瘤(GBM)是惡性度最高的原發性腦瘤之一,在發生部位附近或腦中形成衛星病灶。症狀有頭痛、噁心嘔吐、視力障礙、中風、顱內出血等,治療方法有化療,放射線治療,手術等。

本報告提供復發性多形性膠質母細胞瘤(GBM)的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

復發性多形性膠質母細胞瘤(GBM)概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:大學/研究機關別

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

調查中的產品:大學/研究機關別

開發治療藥的企業

  • AbbVie Inc.
  • Agenus, Inc.
  • Amgen Inc.
  • AngioChem Inc.
  • Apogenix GmbH
  • AstraZeneca Plc
  • Axelar AB
  • BeiGene, Ltd.
  • Boehringer Ingelheim GmbH
  • Boston Biomedical, Inc.
  • Bristol-Myers Squibb Company
  • Cantex Pharmaceuticals, Inc.
  • Cavion LLC
  • Celldex Therapeutics, Inc.
  • Coherus BioSciences, Inc.
  • Cortice Biosciences, Inc.
  • Eisai
  • Eli Lilly and Company
  • EnGeneIC Ltd
  • ERC Belgium SA
  • GenSpera, Inc.
  • Genzyme Corporation
  • GW Pharmaceuticals Plc
  • ImmunoCellular Therapeutics, Ltd.
  • Karyopharm Therapeutics, Inc.
  • Les Laboratoires Servier SAS
  • Medicenna Therapeutics, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • 小野藥品工業
  • Oryx GmbH & Co. KG
  • Pfizer Inc.
  • Stemline Therapeutics, Inc.
  • Threshold Pharmaceuticals, Inc.
  • Tocagen Inc.
  • TRACON Pharmaceuticals, Inc.
  • Vascular Biogenics Ltd.
  • Vaximm AG
  • Virttu Biologics Limited

治療藥的評估

  • 單獨療法的產品
  • 聯合治療的產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • (GWP-42002 + GWP-42003)
  • abemaciclib
  • acalabrutinib
  • afatinib dimaleate
  • AMG-595
  • asinercept
  • AU-101
  • AU-105
  • axitinib
  • AXL-1717
  • AZD-7451
  • bevacizumab biosimilar
  • BGB-290
  • bosutinib
  • buparlisib hydrochloride
  • capmatinib
  • Cellular Immunotherapy for Recurrent Glioblastoma Multiforme
  • Cellular Immunotherapy to Target Interleukein 13 Receptor Alpha-2 for Acute Myelocytic Leukemia and Glioblastoma Multiforme
  • CX-02
  • dacomitinib
  • dasatinib
  • depatuxizumab mafodotin
  • DNX-2401
  • ERC-1671
  • evofosfamide
  • flucytosine ER + vocimagene amiretrorepvec
  • G-200
  • galunisertib
  • golvatinib + lenvatinib
  • golvatinib tartrate
  • HSV-1716
  • ICT-121
  • infigratinib
  • lenvatinib mesylate
  • lonafarnib
  • MDNA-55
  • mibefradil dihydrochloride
  • mipsagargin
  • nabiximols
  • napabucasin
  • NEO-100
  • nilotinib
  • nivolumab
  • ofranergene obadenovec
  • ONC-201
  • Oncolytic Virus for Oncology
  • Oncolytic Virus to Target Carcinoembryonic Antigen for Oncology
  • Oncolytic Virus to Target IL-12 for Oncology
  • OS-2966
  • p28
  • paclitaxel trevatide
  • Parvoryx
  • pazopanib hydrochloride
  • pembrolizumab
  • ramucirumab
  • rilotumumab
  • rindopepimut
  • S-49076
  • selinexor
  • SGT-53
  • SL-701
  • sonidegib phosphate
  • TPI-287
  • TRC-102
  • trebananib
  • vandetanib
  • VEDVDox
  • vorinostat
  • VXM-01

開發中產品的最新趨勢

暫停中的計劃

中止開發的產品

產品開發的里程碑

  • 關註資訊和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8562IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2016, provides an overview of the Recurrent Glioblastoma Multiforme (GBM) (Oncology) pipeline landscape.

Recurrent glioblastoma multiforme (GBM) is one of the most aggressive primary brain tumors. Recurrent tumors develop near the original site or at more distant satellite lesions within the brain. Symptoms include headache, nausea, vomiting, vision problem, seizures and intracranial hemorrhage. Treatment includes chemotherapy, radiation therapy and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Recurrent Glioblastoma Multiforme (GBM) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Recurrent Glioblastoma Multiforme (GBM) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Recurrent Glioblastoma Multiforme (GBM) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 46, 11 and 7 respectively for Similarly, the Universities portfolio in Phase II and Phase I stages comprises 2 and 5 molecules, respectively for Recurrent Glioblastoma Multiforme (GBM).

Recurrent Glioblastoma Multiforme (GBM) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Recurrent Glioblastoma Multiforme (GBM) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Recurrent Glioblastoma Multiforme (GBM) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Recurrent Glioblastoma Multiforme (GBM) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Recurrent Glioblastoma Multiforme (GBM) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Recurrent Glioblastoma Multiforme (GBM) (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Recurrent Glioblastoma Multiforme (GBM) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Recurrent Glioblastoma Multiforme (GBM) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Recurrent Glioblastoma Multiforme (GBM) Overview
  • Therapeutics Development
  • Recurrent Glioblastoma Multiforme (GBM) - Therapeutics under Development by Companies
  • Recurrent Glioblastoma Multiforme (GBM) - Therapeutics under Investigation by Universities/Institutes
  • Recurrent Glioblastoma Multiforme (GBM) - Pipeline Products Glance
  • Recurrent Glioblastoma Multiforme (GBM) - Products under Development by Companies
  • Recurrent Glioblastoma Multiforme (GBM) - Products under Investigation by Universities/Institutes
  • Recurrent Glioblastoma Multiforme (GBM) - Companies Involved in Therapeutics Development
  • Recurrent Glioblastoma Multiforme (GBM) - Therapeutics Assessment
  • Drug Profiles
  • Recurrent Glioblastoma Multiforme (GBM) - Dormant Projects
  • Recurrent Glioblastoma Multiforme (GBM) - Discontinued Products
  • Recurrent Glioblastoma Multiforme (GBM) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Recurrent Glioblastoma Multiforme (GBM), H2 2016
  • Number of Products under Development for Recurrent Glioblastoma Multiforme (GBM) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Recurrent Glioblastoma Multiforme (GBM) - Pipeline by AbbVie Inc, H2 2016
  • Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Agenus, Inc., H2 2016
  • Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Amgen Inc., H2 2016
  • Recurrent Glioblastoma Multiforme (GBM) - Pipeline by AngioChem Inc., H2 2016
  • Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Apogenix GmbH, H2 2016
  • Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Arog Pharmaceuticals, Inc., H2 2016
  • Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Axelar AB, H2 2016
  • Recurrent Glioblastoma Multiforme (GBM) - Pipeline by BeiGene, Ltd., H2 2016
  • Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Boston Biomedical, Inc., H2 2016
  • Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Cantex Pharmaceuticals, Inc., H2 2016
  • Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Cavion LLC, H2 2016
  • Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Coherus BioSciences, Inc., H2 2016
  • Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Cortice Biosciences, Inc., H2 2016
  • Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Eisai Co., Ltd., H2 2016
  • Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Eli Lilly and Company, H2 2016
  • Recurrent Glioblastoma Multiforme (GBM) - Pipeline by EnGeneIC Ltd, H2 2016
  • Recurrent Glioblastoma Multiforme (GBM) - Pipeline by ERC Belgium SA, H2 2016
  • Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Genzyme Corporation, H2 2016
  • Recurrent Glioblastoma Multiforme (GBM) - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Recurrent Glioblastoma Multiforme (GBM) - Pipeline by GW Pharmaceuticals Plc, H2 2016
  • Recurrent Glioblastoma Multiforme (GBM) - Pipeline by ImmunoCellular Therapeutics, Ltd., H2 2016
  • Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Inspyr Therapeutics Inc, H2 2016
  • Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Kadmon Corporation, LLC, H2 2016
  • Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Karyopharm Therapeutics, Inc., H2 2016
  • Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Les Laboratoires Servier SAS, H2 2016
  • Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Medicenna Therapeutics, Inc., H2 2016
  • Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Merck & Co., Inc., H2 2016
  • Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Neonc Technologies Inc, H2 2016
  • Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Novartis AG, H2 2016
  • Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
  • Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Oryx GmbH & Co. KG, H2 2016
  • Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Pfizer Inc., H2 2016
  • Recurrent Glioblastoma Multiforme (GBM) - Pipeline by StemGen S.p.A, H2 2016
  • Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Stemline Therapeutics, Inc., H2 2016
  • Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Threshold Pharmaceuticals, Inc., H2 2016
  • Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Tocagen Inc., H2 2016
  • Recurrent Glioblastoma Multiforme (GBM) - Pipeline by TRACON Pharmaceuticals Inc, H2 2016
  • Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Upsher-Smith Laboratories, Inc., H2 2016
  • Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Vascular Biogenics Ltd., H2 2016
  • Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Vaximm AG, H2 2016
  • Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Virttu Biologics Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Recurrent Glioblastoma Multiforme (GBM) - Dormant Projects, H2 2016
  • Recurrent Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..1), H2 2016
  • Recurrent Glioblastoma Multiforme (GBM) - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Recurrent Glioblastoma Multiforme (GBM), H2 2016
  • Number of Products under Development for Recurrent Glioblastoma Multiforme (GBM) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top